{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:52:41Z","timestamp":1790211161769,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81502308"],"award-info":[{"award-number":["81502308"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773236"],"award-info":[{"award-number":["81773236"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>NSCLC patients with EGFR mutation were at a higher incidence of developing brain metastasis (BM). Patients with BM are associated with high mortality. Reducing BM incidence becomes increasingly significant for NSCLC patients to achieve prolonged survival. The aim of the study was to explore the possible risk factors of developing metachronous BM during EGFR-TKIs treatment, and to identify the potential candidates for prophylactic cranial irradiation (PCI) or the first-line Osimertinib treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 157 consecutive EGFR-mutated advanced NSCLC patients without BM at initial diagnosis in our institution from 2012 and 2018 were retrospectively reviewed. Comparisons of OS were performed based on BM status. The cumulative incidence of metachronous BM was calculated by the Kaplan-Meier method, and the independent risk factors of metachronous BM were investigated by multivariate analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients developing metachronous BM had worse survival (mOS: 22.1\u2009months) than patients not-developing BM (mOS: 44.8\u2009months). Moreover, the multivariate analysis indicated that age\u2009\u2264\u200949\u2009years (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.035), number of extracranial metastases (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.013), and malignant pleural effusion (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002) were independent risk factors of metachronous BM. Furthermore, the 1-year actuarial incidence of developing metachronous BM in patients with no risk factor (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009101), 1 risk factor (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200946), and 2 risk factors (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910) were 7.01, 14.61, and 43.75%, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients developing metachronous BM during EGFR-TKIs treatment have worse outcomes. Our results suggested that EGFR-mutated advanced NSCLC patients with \u22651 risk factors were candidates for PCI or the first-line Osimertinib treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07202-8","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T08:02:53Z","timestamp":1595923373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer"],"prefix":"10.1186","volume":"20","author":[{"given":"Wen","family":"Ouyang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2836-6373","authenticated-orcid":false,"given":"Conghua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,30]]},"reference":[{"key":"7202_CR1","doi-asserted-by":"publisher","unstructured":"Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539\u20134544. https:\/\/doi.org\/https:\/\/doi.org\/10.1200\/JCO.2005.04.4859.","DOI":"10.1200\/JCO.2005.04.4859"},{"key":"7202_CR2","doi-asserted-by":"publisher","unstructured":"Saad AG, Yeap BY, Thunnissen FB, et al. Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma. Cancer. 2008;113:2129\u20132138. https:\/\/doi.org\/https:\/\/doi.org\/10.1002\/cncr.23826.","DOI":"10.1002\/cncr.23826"},{"key":"7202_CR3","doi-asserted-by":"publisher","unstructured":"Lin NU, Wefel JS, Lee EQ, et al. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol2013;14:e407\u2013e416. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/S1470-2045(13)70308-5.","DOI":"10.1016\/S1470-2045(13)70308-5"},{"key":"7202_CR4","doi-asserted-by":"publisher","unstructured":"Kepka L, Cieslak E, Bujko K, et al. Results of the whole-brain radiotherapy for patients with brain metastases from lung cancer: the RTOG RPA intra-classes analysis. Acta Oncol 2005;44:389\u2013398. https:\/\/doi.org\/https:\/\/doi.org\/10.1080\/02841860510029699.","DOI":"10.1080\/02841860510029699"},{"key":"7202_CR5","doi-asserted-by":"publisher","unstructured":"Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380\u20132388. https:\/\/doi.org\/https:\/\/doi.org\/10.1056\/NEJMoa0909530.","DOI":"10.1056\/NEJMoa0909530"},{"key":"7202_CR6","doi-asserted-by":"publisher","unstructured":"Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum-Pemetrexed in EGFR T790M-positive lung Cancer. N Engl J Med 2017;376:629\u2013640. https:\/\/doi.org\/https:\/\/doi.org\/10.1056\/NEJMoa1612674.","DOI":"10.1056\/NEJMoa1612674"},{"key":"7202_CR7","doi-asserted-by":"publisher","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung Cancer. N Engl J Med 2018;378:113\u2013125. https:\/\/doi.org\/https:\/\/doi.org\/10.1056\/NEJMoa1713137.","DOI":"10.1056\/NEJMoa1713137"},{"key":"7202_CR8","doi-asserted-by":"publisher","unstructured":"Sperduto PW, Yang TJ, Beal K, et al. The effect of gene alterations and tyrosine kinase inhibition on survival and cause of death in patients with adenocarcinoma of the lung and brain metastases. Int J Radiat Oncol Biol Phys 2016;96:406\u2013413. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.ijrobp.2016.06.006.","DOI":"10.1016\/j.ijrobp.2016.06.006"},{"key":"7202_CR9","doi-asserted-by":"publisher","unstructured":"Han G, Bi J, Tan W, et al. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?. Oncotarget. 2016;7:56998\u201357010. https:\/\/doi.org\/https:\/\/doi.org\/10.18632\/oncotarget.10933.","DOI":"10.18632\/oncotarget.10933"},{"key":"7202_CR10","doi-asserted-by":"publisher","unstructured":"Bhatt VR, D'Souza SP, Smith LM, Cushman-Vokoun AM, Noronha V, Verma V, et al. Epidermal growth factor receptor mutational status and brain metastases in non-small-cell lung Cancer. J Glob Oncol 2016;3:208\u2013217. https:\/\/doi.org\/https:\/\/doi.org\/10.1200\/JGO.2016.003392.","DOI":"10.1200\/JGO.2016.003392"},{"key":"7202_CR11","doi-asserted-by":"publisher","unstructured":"Fan Y, Xu X, Xie C. EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data. Onco Targets Ther 2014;7:2075\u20132084. https:\/\/doi.org\/https:\/\/doi.org\/10.2147\/OTT.S67586.","DOI":"10.2147\/OTT.S67586"},{"key":"7202_CR12","doi-asserted-by":"publisher","unstructured":"Komaki R, Scott CB, Byhardt R, et al. Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on four radiation therapy oncology group (RTOG) studies in inoperable nonsmall-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1998;42:263\u2013267. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/S0360-3016(98)00213-2.","DOI":"10.1016\/S0360-3016(98)00213-2"},{"key":"7202_CR13","doi-asserted-by":"publisher","unstructured":"Gore EM, Bae K, Wong SJ, et al. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol 2011;29:272\u2013278. https:\/\/doi.org\/https:\/\/doi.org\/10.1200\/JCO.2010.29.1609.","DOI":"10.1200\/JCO.2010.29.1609"},{"key":"7202_CR14","doi-asserted-by":"publisher","unstructured":"Sun A, Bae K, Gore EM, et al. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol 2011;29:279\u2013286. https:\/\/doi.org\/https:\/\/doi.org\/10.1200\/JCO.2010.29.6053.","DOI":"10.1200\/JCO.2010.29.6053"},{"key":"7202_CR15","doi-asserted-by":"publisher","unstructured":"Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014;4:1046\u20131061. https:\/\/doi.org\/https:\/\/doi.org\/10.1158\/2159-8290.cd-14-0337.","DOI":"10.1158\/2159-8290.cd-14-0337"},{"key":"7202_CR16","doi-asserted-by":"publisher","unstructured":"Ballard P, Yates JW, Yang Z, et al. Preclinical comparison of Osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 2016;22:5130\u20135140. https:\/\/doi.org\/https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-0399.","DOI":"10.1158\/1078-0432.ccr-16-0399"},{"key":"7202_CR17","doi-asserted-by":"publisher","unstructured":"Vansteenkiste J, Reungwetwattana T, Nakagawa K, et al. CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): data from the FLAURA study. Ann Oncol 2017;28. https:\/\/doi.org\/https:\/\/doi.org\/10.1093\/annonc\/mdx729.007.","DOI":"10.1093\/annonc\/mdx729.007"},{"key":"7202_CR18","doi-asserted-by":"publisher","unstructured":"Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252\u20137259. https:\/\/doi.org\/https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0713.","DOI":"10.1158\/1078-0432.CCR-04-0713"},{"key":"7202_CR19","doi-asserted-by":"publisher","unstructured":"Roeper J, Griesinger F. Epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer: what is the preferred first-line therapy?. Curr Opin Oncol 2019 ;31:1\u20137. https:\/\/doi.org\/https:\/\/doi.org\/10.1097\/CCO.0000000000000495.","DOI":"10.1097\/CCO.0000000000000495"},{"key":"7202_CR20","doi-asserted-by":"publisher","unstructured":"Arrieta O, Saavedra-Perez D, Kuri R, et al. Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis. BMC Cancer 2009;9:119. https:\/\/doi.org\/https:\/\/doi.org\/10.1186\/1471-2407-9-119.","DOI":"10.1186\/1471-2407-9-119"},{"key":"7202_CR21","doi-asserted-by":"publisher","unstructured":"Ma X, Zhu H, Guo H, et al. Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma. Oncotarget. 2016;7:81906\u201381917. https:\/\/doi.org\/https:\/\/doi.org\/10.18632\/oncotarget.11918.","DOI":"10.18632\/oncotarget.11918"},{"key":"7202_CR22","doi-asserted-by":"publisher","unstructured":"Barlesi F, Mazieres J, Merlio JP, et al. Biomarkers France contributors. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French cooperative thoracic intergroup (IFCT). Lancet. 2016;387:1415\u20131426. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/S0140-6736(16)00004-0.","DOI":"10.1016\/S0140-6736(16)00004-0"},{"key":"7202_CR23","doi-asserted-by":"publisher","unstructured":"Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947\u2013957. https:\/\/doi.org\/https:\/\/doi.org\/10.1056\/NEJMoa0810699.","DOI":"10.1056\/NEJMoa0810699"},{"key":"7202_CR24","doi-asserted-by":"publisher","unstructured":"Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121\u2013128. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/S1470-2045(09)70364-X.","DOI":"10.1016\/S1470-2045(09)70364-X"},{"key":"7202_CR25","doi-asserted-by":"publisher","unstructured":"Wu YL, Zhou C, Cheng Y, et al. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol 2013;24:993\u2013999. https:\/\/doi.org\/https:\/\/doi.org\/10.1093\/annonc\/mds529.","DOI":"10.1093\/annonc\/mds529"},{"key":"7202_CR26","doi-asserted-by":"publisher","unstructured":"Weber B, Winterdahl M, Memon A, et al. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol 2011;6:1287\u20131289. https:\/\/doi.org\/https:\/\/doi.org\/10.1097\/JTO.0b013e318219ab87.","DOI":"10.1097\/JTO.0b013e318219ab87"},{"key":"7202_CR27","doi-asserted-by":"publisher","unstructured":"Lee YJ, Choi HJ, Kim SK, et al. Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with non small-cell lung cancer. Cancer. 2010;116:1336\u20131343. https:\/\/doi.org\/https:\/\/doi.org\/10.1002\/cncr.24877.","DOI":"10.1002\/cncr.24877"},{"key":"7202_CR28","doi-asserted-by":"publisher","unstructured":"Arrieta O, Villarreal-Garza C, Zamora J, et al. Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation. Radiat Oncol 2011;6:166. https:\/\/doi.org\/https:\/\/doi.org\/10.1186\/1748-717X-6-166.","DOI":"10.1186\/1748-717X-6-166"},{"key":"7202_CR29","doi-asserted-by":"publisher","unstructured":"Ji Z, Bi N, Wang J, et al. Risk factors for brain metastases in locally advanced non-small cell lung cancer with definitive chest radiation. Int J Radiat Oncol Biol Phys 2014;89:330\u2013337. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.ijrobp.2014.02.025.","DOI":"10.1016\/j.ijrobp.2014.02.025"},{"key":"7202_CR30","doi-asserted-by":"publisher","unstructured":"Ceresoli GL, Reni M, Chiesa G, et al. Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis. Cancer. 2002;95:605\u2013612. https:\/\/doi.org\/https:\/\/doi.org\/10.1002\/cncr.10687.","DOI":"10.1002\/cncr.10687"},{"key":"7202_CR31","doi-asserted-by":"publisher","unstructured":"Gaspar LE, Chansky K, Albain KS, et al. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the southwest oncology group. J Clin Oncol 2005;23:2955\u20132961. https:\/\/doi.org\/https:\/\/doi.org\/10.1200\/JCO.2005.08.026.","DOI":"10.1200\/JCO.2005.08.026"},{"key":"7202_CR32","doi-asserted-by":"publisher","unstructured":"Robnett TJ, Machtay M, Stevenson JP, et al. Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol 2001;19:1344\u20131349. https:\/\/doi.org\/https:\/\/doi.org\/10.1200\/JCO.2001.19.5.1344.","DOI":"10.1200\/JCO.2001.19.5.1344"},{"key":"7202_CR33","doi-asserted-by":"publisher","unstructured":"Dimitropoulos C, Hillas G, Nikolakopoulou S, et al. Prophylactic cranial irradiation in non-small cell lung cancer patients: who might be the candidates?. Cancer Manag Res 2011;3:287\u2013294. https:\/\/doi.org\/https:\/\/doi.org\/10.2147\/CMR.S22717.","DOI":"10.2147\/CMR.S22717"},{"key":"7202_CR34","doi-asserted-by":"publisher","unstructured":"Cedr\u00e9s S, Nu\u00f1ez I, Longo M, et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer 2011;12:172\u2013179. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.cllc.2011.03.019.","DOI":"10.1016\/j.cllc.2011.03.019"},{"key":"7202_CR35","doi-asserted-by":"publisher","unstructured":"An N, Jing W, Wang H, et al. Risk factors for brain metastases in patients with non-small-cell lung cancer. Cancer Med 2018;7:6357\u20136364. https:\/\/doi.org\/https:\/\/doi.org\/10.1002\/cam4.1865.","DOI":"10.1002\/cam4.1865"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07202-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07202-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07202-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T19:12:38Z","timestamp":1627585958000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07202-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,30]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7202"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07202-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.17604\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.17604\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.17604\/v2","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,30]]},"assertion":[{"value":"14 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of Zhongnan hospital of Wuhan University. Ethics Committee approved verbal informed consent. Because our study is retrospective, and we collected and analyzed the data of enrolled patients by reviewing their electronic medical records. The information of enrolled patients is anonymous. The collection, analysis and publication of the data will not infringe enrolled patients\u2019 health, safety and privacy. Informed consent was obtained orally from the included patients by telephone.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"699"}}